## Annual Summary Form



| a) Date of<br>activity | b) Activity area and<br>Category   | c) Description of the activity and benefit gained from undertaking it   | d) Fo<br>hrs | ormal<br>crd | e) Info<br>hrs | ormal<br>crd |
|------------------------|--|---|--------------|--------------|----------------|--------------|
| 2015-08-26             | Formal/Educat<br>ional:<br>Attendance at<br>Conferences<br>or Scientific<br>Meetings | Attendance of the 44th Annual Meeting of the European Environmental<br>Mutagenesis and Genomics Society<br>23-26 August 2015 Prague, Czech Republic:<br>Day 3<br>Lectures 8:30 - 10:30; 11:00 - 12:00<br>http://eemgsmeeting2015.eu/<br>Lectures on a wide range of topics broadly covering chemicals of<br>concern in relation to carcinogenicity and mutagenicity.<br>I gained increase knowledge of the many mechanisms and factors<br>involved in the toxicological risk chemicals can pose, whether people<br>are exposed directly or through their environment. Whilst the topics<br>were not directly related to my main work practice of cosmetics, many<br>of them had transferable elements. For example the length of time a<br>chemical can remain on the skin, background exposure through food<br>and interconnectivity of metabolic pathways were just some of the<br>topics that provided me with information to take back to my company.<br>This enabled me to change my work practice by considering more data<br>when assessing cosmetic products. Those with ingredient concerns<br>over high level of exposure were then considered alongside the<br>information I had gathered, for example a likely background dose from<br>other sources such as food which altered the outcome of risk<br>assessments.<br>I shared the information learned with my colleagues which resulted in<br>the company including these background levels in risk assessment<br>and ingredient specifications. They are sending someone back next<br>year to update the information gathered and are likely to do so for the<br>foreseeable future. | 3            | 6            |                |              |
| 2015-08-25             | Formal/Educat<br>ional:<br>Attendance at<br>Conferences                              | Attendance of the 44th Annual Meeting of the European Environmental<br>Mutagenesis and Genomics Society 23-26 August 2015 Prague, Czech<br>Republic:<br>Day 2<br>Lectures 8:30 - 10:30; 11:00 - 12:00; 13:30 - 14:30; 15:30 - 16:30   | 6            | 12           |                |              |

| 2015-08-24 | or Scientific<br>Meetings             | Poster presentations and session 16:30 - 18:00<br>http://eemgsmeeting2015.eu/<br>In addition to the above, Days 1 and 2 had poster sessions where data<br>from numerous studies were on display with scientists who had<br>conducted them. This enabled me to talk in depth with those who had<br>investigated areas of interest to myself and the company, including<br>heavy metal and carcinogen exposure from product packaging. I was<br>able to take away valuable details and insight into these processes<br>which enabled me to include them in our company database. This<br>allowed me to integrate more toxicological data into my work practice<br>which was particularly beneficial when we started assessing cosmetic<br>packaging alongside the same restrictions as food packaging. These<br>specifications were also used for the companies ingredient<br>specifications which are required to be used by all clients whose<br>products we were responsible for.<br>Attendance of the 44th Annual Meeting of the European Environmental<br>Mutagenesis and Genomics<br>Society 23-26 August 2015 Prague, Czech Republic:<br>Day 1<br>Lectures 8:30 - 10:30; 11:00 - 12:00; 13:30 - 15:30; 16:30 - 17:30<br>Poster presentations and session 17:30 - 19:30<br>http://eemgsmeeting2015.eu/<br>Same as days 2 and 3. Certificate of attendance included in previous<br>electronic submission. | 8  | 16 |  |
|------------|---------------------------------------|--|----|----|--|
| 2015-05-29 | Self-directed<br>Learning:<br>Reading | Average of 2 hours per week:<br>- Review of EU and worldwide Regulation changes for Cosmetics,<br>Households and Toy products<br>- New scientific test approaches and review papers such as Direct<br>Peptide Reactivity Assay (DPRA), the KeratinoSens, and the human<br>Cell Line Activation Test (hCLAT) validation progress and  | 20 | 20 |  |

| 2015-04-27 | Work Based<br>Learning:<br>Supervising<br>Colleagues or<br>Students | refinement - Toxicological reviews of chemicals - Papers on toxicological processes and analytical methods, e.g. threshold of toxicological concern, decision tree approaches (cramer classes etc.), application of read across guidance by the European Chemicals Agency - Human study data, for example prevalence of MIT allergy across Europe For at least an hour each week I was given time to read up on the latest toxicological developments. New test approaches were reviewed to see if we could include information in our toxicology database, which was the case for many of the in vitro sensitization tests. Regulatory changes were reviewed and anticipated to ensure clients were prepared in plenty of time rather than having to rapidly reformulate or withdraw products. Chemical toxicology profiles were regularly reviewed to ensure the safe and legal use was as accurate and up to date as possible. New studies were analyzed to update client training presentations and blogs. Without this learning I would not have been able to maintain the quality of my services. Clients benefitted from this by receiving professional advice and practice that was up to date with the latest advances in the field of toxicology and relevant regulations. Training members of staff from the compliance team in toxicological safety assessments:     Running through processes required     Review of EU Cosmetic required test data     Toxicological review training of ingredients to final product as a whole     Report production of Cosmetic Product Safety Assessment I provided the above training to improve the performance of other team members by enabling them to understand the processes and strategies of the toxicology team. This allowed for greater cross communication between the two teams and sharing of work. Clients were then able to have their queries answered when certain staff were busy and issues were identified earlier from review by multiple individuals. | 4 | 8 |  |
|------------|---|---|---|---|--|
| 2015-04-22 | Work Based<br>Learning:<br>Participation<br>in Appraisal            | Review of main duties and responsibilities<br>Performance over the past 6 months/year<br>Aims/tasks for the next 6 months/year<br>Likes and dislikes<br>Challenging elements  | 2 | 2 |  |

|            | and Goal<br>Setting   | Improvement actions<br>Training/experience requirements for next year<br>Objective setting<br>Scoring of personal factors/areas<br>Appraisals provided me with feedback to work on and improve my<br>performance, whether that was focused on toxicology or other skills<br>such as project management, communication, organization or time<br>keeping. This allowed me to improve my performance over the year<br>and become one of the most productive members of staff. My<br>increased efficiency was beneficial to clients who received their work<br>back more quickly and to a higher standard.   |    |    |  |
|------------|---|--|----|----|--|
| 2015-03-10 | Work Based<br>Learning:<br>Receiving<br>Coaching<br>From Others | Talk by Dr Emma Marczylo on Genomic/Transcriptomic (G/T) techniques:         - How to review G/T data         - Reliability of G/T tests         - Future G/T tests and how to utilize them for safety assessments         - Incorporating big data G/T with other relevant toxicological pathways and analysis         This talk was provided to improve my knowledge around G/T techniques and consequently be able to use data from them to improve the toxicology database. It also showed how in the future the company could incorporate these approaches with a battery of testing to provide more comprehensive data on chemicals, particularly those where currently data is lacking. This enabled me to more accurately produce safety assessments and gave me the ability to review data I could not have done previously. Therefore clients and colleagues could more accurately rely on reports that included a greater array of information. | 2  | 4  |  |
| 2015-03-10 | Work Based<br>Learning:<br>Discussions<br>with                  | Average 1 hour meeting per week, content can include:         - Approach outcome of scientific body opinions, such as recommended use limits and product types         - Format of our reports; content, data, requirements, legal statements         - Training plans         - Review of toxicological processes   | 10 | 20 |  |

| Colleagues | <ul> <li>CLP additivity approach discussions on relevance and when to use it</li> <li>Outcome of scientific papers</li> <li>Service provisions and data requirements</li> </ul>  |                  |   |
|------------|--|------------------|---|
|            | These sessions allowed me to see how others approached common problems<br>and alternative solutions I would not have come up with by myself. It also<br>enabled the company to provide a uniform response to issues which helped<br>clients understand them more easily. In addition it expanded my knowledge<br>by being able to focus on one topic and then have feedback on others<br>provided in these meetings. |                  |   |
|            |  | f) Total Credits | 5 |
|            |  |                  |   |

By submitting this form, you declare that the information provided above is a true and accurate account of your CPD activities

Registered Charity No. 277981 Incorporated by Royal Charter